Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 14,479

Document Document Title
WO/2017/221869A1
Provided is a method for producing a substituted polycyclic pyridone derivative. A method for producing a compound represented by formula (II), which is characterized in that a compound represented by formula (I) is reacted with a compou...  
WO/2017/219808A1
Provided are a compound as shown in formula (I) usable as a hepatitis C virus inhibitor, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, usable to treat hepatitis C virus (HCV) infections or hepa...  
WO/2017/215588A1
Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (1) or a pharmaceutically acceptable salt thereof.  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/218843A1
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof. (Formu...  
WO/2017/218960A1
Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagno...  
WO/2017/212425A1
The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as define...  
WO/2017/211759A1
The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.  
WO/2017/211760A1
The present invention relates to novel antibacterial compounds (1) as defined below, pharmaceutical compositions containing them and their use as antimicrobials. A compound of formula (1): A-L1-Y-L2-R-B, wherein A is a cyclic group havin...  
WO/2017/213210A1
The present invention relates to a compound potentially useful as a prophylactic or therapeutic drug for cancer.  
WO/2017/211303A1
Provided are certain pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as...  
WO/2017/207540A1
The present invention relates to novel anthracycline derivatives comprising two oxazolidine cycles and the preparation of said anthracycline derivatives. Furthermore, antibody-drug conjugates (ADCs) comprising the novel anthracycline der...  
WO/2017/208105A1
The present invention provides novel crystalline form A of dolutegravir sodium with characteristic diffraction peaks at 6.3, 7.8, 9.3, 11.4, 12.4, 13.5, 12.7, 15.1, 15.8, 18.3, 19.0, 19.6, 20.7, 22.8, 23.1, 24.3 and 25.8 ± 0.2 degree tw...  
WO/2017/209155A1
Provided are: a novel sulfonamide compound having ribonucleotide reductase inhibitory activity or a salt thereof; and a pharmaceutical composition which contains this sulfonamide compound or a salt thereof as an active ingredient. A comp...  
WO/2017/210545A1
Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided...  
WO/2017/177004A8
Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation ...  
WO/2017/202390A1
Provided in the present invention is a heterocyclic compound serving as an FGFR4 (fibroblast growth factor receptor 4) inhibitor. Specifically, provided in the present invention is the compound shown in formula (I), including isomers (en...  
WO/2017/201846A1
A preparation method of an antibacterial oxazolidinone medicine and an intermediate thereof. The preparation method avoids using explosive azide compounds and allergenic and genotoxic chlorides, and avoids a column chromatography purific...  
WO/2017/004500A9
The invention provides novel compounds having the general formula I: (I) wherein R1, X, Z1, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using th...  
WO/2017/202748A1
Compounds of the formula (I) in which R1 and R2 have the meanings indicated in Claim 1,are inhibitors of ATR, and can be employed for the treatment of diseases such as cancer.  
WO/2017/198102A1
Provided are a substituted macrocyclic quinoxaline compound and a pharmaceutical composition and use thereof, wherein the macrocyclic quinoxaline compound is the compound as shown in formula (I), or a polymorph, a pharmaceutically accept...  
WO/2017/198341A1
The present invention relates to macrocyclic indole derivatives of general formula (I) : (I), in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparin...  
WO/2017/199265A1
The present disclosure relates to compounds of Formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms thereof and pharmaceutical com...  
WO/2017/200863A1
The present invention provides N-[3-[2-Amino-5-(1,1-difluoroethyl) -4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-p henyl]-5- (trifluoromethyl)pyridine-2-carboxamide, i.e. the compound of Formula I: [Formula should be inserte...  
WO/2017/196261A1
The present disclosure described provides novel dual inhibition compounds that specifically target the JAK-STAT and HDAC pathways, two distinct cellular pathways that are useful in the treatment of various diseases and disorders. In cert...  
WO/2017/196210A1
The invention relates to the chemistry of organic compounds, to pharmacology and to medicine, and pertains to the prevention and treatment of human and animal diseases associated with metabolic disorders of bone tissues and/or cartilage ...  
WO/2017/190345A1
Provided is the design, synthesis and applications of molecular fluorophores for bioimaging in the short wavelength infrared window (1000-1700 nm). The molecular fluorophores compound comprise structures with electron accepting aromatic ...  
WO/2017/191304A1
The present invention relates to new compounds of general formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially α2δ-1 subunit of voltage-gated calcium channels ...  
WO/2017/192930A1
The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and comp...  
WO/2017/192961A1
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...  
WO/2017/189661A1
The present invention comprises compounds of Formula (I) wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein...  
WO/2017/186148A1
Disclosed is a compound of Formula (Ⅰ) or a pharmaceutically acceptable salt thereof, wherein the variables are described herein. Also disclosed is a process for the preparation of compounds, their pharmaceutical compositions comprisin...  
WO/2017/181947A1
The present invention provides a substituted diamine carbamate, and a pharmaceutical composition and application thereof. The diamine carbamate is a compound represented by formula (I), or a crystalline form, pharmaceutically acceptable ...  
WO/2017/179002A1
The invention relates to antibacterial compounds of formula (I), wherein U1 represents N or CH, U2 represents N or CH, U3 represents N or CH, it being understood that at most two of U1, U2, U3 can represent N at the same time; V1 represe...  
WO/2017/177828A1
The present invention relates to a novel oxazolidinone-fluoroquinolone derivative and uses, and relates to the field of chemical drugs. The present invention also relates to a compound represented by formula (I), a pharmaceutically accep...  
WO/2017/177837A1
The present invention relates to a heterocyclic-substituted pyridinopyrimidinone derivative, and the use thereof as a therapeutically effective cyclin-dependent kinase (CDK) inhibitor. In particular, the present invention relates to the ...  
WO/2017/155942A3
Disclosed are substituted heterocycles compounds including substituted pyrazoles, substituted pyrimidines, and substitute triazoles. The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC and may be util...  
WO/2017/176981A1
Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorde...  
WO/2017/177004A1
Compunds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation o...  
WO/2017/175091A1
This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17 -tetrahydro-2H-8,4-(metheno)pyrazolo[4,3- h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlat inib) maleate. The inv...  
WO/2017/175147A1
Disclosed are compounds having the formula (I-N), wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically ac...  
WO/2017/170765A1
Provided are: a novel nitrogen-containing heterocyclic compound, which has an aldosterone synthase-inhibiting activity and, therefore, is useful for preventing and/or treating various diseases or symptoms associated with aldosterone and/...  
WO/2017/170830A1
Provided is a compound having an MAGL-inhibiting effect, and anticipated to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, amy...  
WO/2017/165732A1
The present disclosure provides therapeutic methods of treating a cancer patient with TG02 and a second therapeutic agent, e.g., TG02 and an immune checkpoint inhibitor, TG02 and a COX-2 inhibitor, or TG02 and an immune checkpoint inhibi...  
WO/2017/165607A1
Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) including but not limited to conjugates comprising FK-506 and ascomycin. Other embodiments include compositions (e.g., pharmaceutical composit...  
WO/2017/153919A1
The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: (I) and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compou...  
WO/2017/153513A1
A compound of formula (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from the group consisiting of H, halo, C1-4 alkoxy, C1-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, NH-C1-4 alkyl and cyano; R2a...  
WO/2017/153519A1
A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2;R N is H or Me; R1 is optionally one or more halo or methyl groups;R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH2 OH;...  
WO/2017/153515A1
A compound of formula (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from H, halo, methyl and methoxy; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me;...  
WO/2017/153518A1
A compound of formula (Ia), (Ib) or (Ic) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2O...  

Matches 601 - 650 out of 14,479